Steven Cohen Aeglea Bio Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$6.03 - $7.95 $2.83 Million - $3.73 Million	-469,765 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.32 - $8.38 $6.51 Million - $8.63 Million	-1,030,235 Reduced 68.68%	469,765 $3.27 Million
Q1 2021 May 17, 2021	SELL	$6.76 - $8.57 $9.6 Million - $12.2 Million	-1,420,553 Reduced 48.64%	1,500,000 $11.9 Million
Q4 2020 Feb 16, 2021	BUY	$7.02 - $9.83 $20.5 Million - $28.7 Million	2,920,553 New	2,920,553 $23 Million
Q4 2018 Feb 14, 2019	SELL	$6.51 - $10.19 $1.73 Million - $2.71 Million	-265,636 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.24 - $11.0 $2.19 Million - $2.92 Million	265,636 New	265,636 $2.54 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.